Table 1.
(cont.) Baseline characteristics.
| Overall (n = 44) |
Non-Survivors (n = 12) |
Survivors (n = 32) |
p-value | |
|---|---|---|---|---|
| Medication | ||||
| ACE-inhibitor, n (%) | 17 (38.6 %) | 3 (25.0 %) | 14 (43.8 %) | 0.255 |
| AT-1 antagonists, n (%) | 38 (86.4 %) | 10 (83.3 %) | 28 (87.5 %) | 0.719 |
| Betablocker, n (%) | 38 (86.4 %) | 10 (83.3 %) | 28 (87.5 %) | 0.719 |
| Neprilysin-inhibitor, n (%) | 4 (9.1 %) | 2 (16.7 %) | 2 (6.3 %) | 0.267 |
| Thiazide, n (%) | 39 (88.6 %) | 10 (83.3 %) | 29 (90.6 %) | 0.497 |
| Loop diuretics, n (%) | 39 (88.6 %) | 10 (83.3 %) | 29 (90.6 %) | 0.497 |
| Torasemide, mg | 15.0 (10.0–30.0) | 30.0 (15.0–40.0) | 12.5 (10.0–22.5) | 0.016 |
| Allopurinol, n (%) | 14 (31.8 %) | 6 (50.0 %) | 8 (25.0 %) | 0.112 |
| Metformin, n (%) | 6 (13.7 %) | 1 (8.3 %) | 5 (15.6 %) | >0.99 |
| Echocardiographic parameter | ||||
| LVEF, % | 40.0 (30.0–52.8) | 36.0 (25.0–52.5) | 45.0 (30.0–53.5) | 0.435 |
| LVEDD, mm/m2 | 50.0 (45.3–58.8) | 45.5 (38.8–49.0) | 54.0 (47.5–60.0) | 0.045 |
| RVD1, mm | 39.0 (36.0–46.5) | 39.0 (38.0–47.0) | 39.0 (35.0–47.0) | 0.592 |
| TAPSE, mm | 15.0 (13.0–20.0) | 13.5 (8.8–18.5) | 16.0 (13.0–20.0) | 0.269 |
| LA size, cm2 | 26.3 (21.0–34.8) | 27.1 (22.1–36.2) | 25.0 (20.7–35.0) | 0.462 |
| RA size, cm2 | 26.0 (20.5–30.4) | 21.9 (15.2–32.3) | 26.8 (20.8–30.7) | 0.386 |
SBP = systolic blood pressure, DBP = diastolic blood pressure, CKD = chronic kidney disease, MI = myocardial infarction, NYHA = New York Health Association, LVEF = left ventricular ejection fraction, LVEDD = left ventricular enddiastolic diameter, RVD = right ventricular diameter, TAPSE = tricuspid annular plane systolic excursion, LA = left atrium, RA = right atrium; differences were calculated using chi-square or Fisher's exact test for categorical variables, and Student's t-test or the Mann–Whitney U test for continuous variables, as appropriate.